Skip to main navigation Skip to search Skip to main content

Evaluation of Efficacy, Safety and Tolerability of NGM282 (aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

  • Pianko, Stephen (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusFinished
Effective start/end date19/12/19 → 18/12/24

Keywords

  • clinical trial
  • treatment efficacy
  • treatment safety
  • cirrhosis
  • hepatitis

Clinical Trial Phase

  • Phase II